Quick Answer
Benitec Biopharma Inc. reported Net Income Loss of -$37.92 million for the year ending 2025.
- Benitec Biopharma Inc. showed a decrease of -74.3% in Net Income Loss from 2024 to 2025.
- This data is from Benitec Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on September 22, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$1.15 million | Q4 2019: -$2.09 million | Q1 2020: -$2.10 million | Q3 2020: -$2.72 million | Q4 2020: -$3.25 million | Q1 2021: -$3.91 million | Q3 2021: -$5.05 million | Q4 2021: -$4.82 million | Q1 2022: -$3.28 million | Q3 2022: -$5.09 million | Q4 2022: -$5.41 million | Q1 2023: -$4.40 million | Q3 2023: -$5.95 million | Q4 2023: -$6.80 million | Q1 2024: -$4.28 million | Q3 2024: -$5.06 million | Q4 2024: -$9.55 million | Q1 2025: -$9.35 million | Q2 2025: -$8.81 million | Q3 2025: -$8.97 million | Q4 2025: -$11.84 million.
- Over the full 7 years of available data (2019 to 2025), Benitec Biopharma Inc.'s Net Income Loss has declined by 1,553.3%.
- Historical annual values: Fiscal year 2025: -$37.92 million | Fiscal year 2024: -$21.75 million | Fiscal year 2023: -$19.56 million | Fiscal year 2022: -$18.21 million | Fiscal year 2021: -$13.88 million | Fiscal year 2020: -$8.27 million | Fiscal year 2019: $2.61 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: